Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry
Brendon M. Patierno(Duke University), Jennifer A. Freedman(Duke Medical Center), Jason A. Somarelli(Duke Medical Center), Dadong Zhang(Precision for Medicine (United States)), David S. Hsu(Duke University), Jiaoti Huang(Space Science Institute), Kouros Owzar(Duke University), Andrew J. Armstrong(Duke University), Shannon J. McCall(Duke Medical Center), Tyler A. Allen(North Carolina State University), Daniel J. George(Duke University), Brant A. Inman(Duke Medical Center), John Pierce Wise(University of Louisville), Steven R. Patierno(George Washington University), Rick A. Kittles(Morehouse School of Medicine), Lingfan Xu(Duke University), Santosh Gupta(Duke University), Xufeng Chen(Duke University), Yanjing Li(Duke University), Sandra S. Wise(University of Louisville), Kathryn E. Ware(Duke University), Xiaodi Qin(Duke Cancer Institute), Wen-Chi Foo(Duke University), Simon G. Gregory(Center for Human Genetics)
Cited by 4
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k